
Therapeutic apheresis
Plasmapheresis with in-house GEMMA technology and direct medical supervision.
Explore therapeutic apheresis
Clinical data, precision technology, plasmapheresis and cellular medicine in the service of health that is more preventive, more personalized and more intelligent.
Our clinical practice
Four connected areas. One methodology: clinical assessment, a personalized protocol and follow-up.

Plasmapheresis with in-house GEMMA technology and direct medical supervision.
Explore therapeutic apheresis
Cell therapy, exosomes and peptides within individualized protocols.
Explore regenerative medicineMedical history and biomarkers to guide each therapeutic decision.
Explore advanced diagnosticsPreventive assessment, precision medicine and clinical response monitoring.
Explore clinical longevityIndications, available evidence and regulatory status are reviewed with each patient. Individual results may vary.
All protocolsMedical team

Medical Director
Postgraduate training at Pavlov University. Apheresis Technology co-founder and plasmapheresis author.
Specialist in therapeutic apheresis. Postgraduate training at Pavlov First Saint Petersburg State Medical University. Co-founder of Apheresis Technology. Author of the first book on plasmapheresis published in Latin America. 25+ years of specialized clinical practice.

Gynecology
Trained at Pavlov University. Gynecology, hormonal health and ISUOG membership.
Gynecologist trained at Akademik Pavlov State Medical University, Russia. Member of the International Society of Ultrasound in Obstetrics and Gynecology. Specialist in female hormonal health, climacteric and fertility.

International Coordination · New York
Clinical coordination from New York. Training at PUCE, Grenoble Alpes and EPFL.
Coordinates care for international patients from New York. Medical training at PUCE, with studies at Université Grenoble Alpes and École Polytechnique Fédérale de Lausanne. Speaks five languages.
Scientific authority
Professor and Head of the Therapeutic Apheresis Department at Pavlov University, Saint Petersburg. Author of 360+ scientific papers and 25 inventions and patents.
Scientific background
International scientific participation
Dr. Gerardo Zumbana · Regene Global & ISSCA. Plasma exchange and plasmapheresis in regenerative medicine and longevity.
Preventive medicine and longevity
80+ biomarkers, clinical assessment and follow-up. A longevity approach connecting diagnostics, plasmapheresis and regenerative medicine.
Explore longevityIntravenous formulations under medical indication, as part of an individualized plan.
View IV therapiesClinical information
Clinical indications, care pathways and explanations from the medical team.
Clinical Conditions
NexusMed focuses its practice on conditions where the combination of therapeutic plasmapheresis, cell therapy and regenerative medicine has documented clinical support. We don't treat everything. We treat where we can generate measurable impact.
Therapeutic plasmapheresis physically removes the pathological antibodies that attack healthy tissue. Recognized by ASFA as a first-line treatment for multiple autoimmune conditions.
Conditions we treat
Several autoimmune neurological conditions carry an ASFA category I indication for plasmapheresis. Our protocols are designed to remove the autoantibodies responsible for neurological damage.
Conditions we treat
Apheresis with liver-support systems is indicated in conditions where detoxification function is compromised. Our technology allows us to act directly on the circulating compounds the liver cannot process, in coordination with the patient's treating hepatologist.
Clinical conditions treated
Therapeutic apheresis and regenerative protocols are indicated for patients with rheumatologic disease refractory to biologic therapies, immunomodulators or conventional immunosuppressive regimens.
Clinical conditions treated
Our practice in oncology is strictly complementary. We do not replace chemotherapy, radiotherapy or hematologic regimens. We always work in coordination with the patient's treating oncologist.
Support procedures
Selective apheresis can directly remove pathological lipoproteins when conventional medication fails to reach clinical targets. We also apply regenerative protocols in selected patients.
Conditions we treat
For patients without active disease seeking long-term health optimization. A comprehensive program with expanded biomarkers, biological age, genetic analysis and personalized regenerative protocols.
Areas of optimization
Led by Dr. Irina Podaneva. A specialized practice with an integrative approach, combining clinical gynecology with the regenerative-medicine principles that define the center.
Areas of practice
Every clinical indication is evaluated individually. The suitability of any protocol is determined during the initial consultation with one of our specialist physicians, taking into account medical history, complementary studies and the patient's goals.
Clinical Programs
NexusMed's clinical practice is structured into two categories of care based on each patient's therapeutic goal.
For patients with an active clinical diagnosis of autoimmune, neurological, liver, rheumatologic or oncologic disease who require specialized intervention.
Duration varies according to condition and clinical response.
View therapeutic protocolsFor patients without active disease seeking advanced clinical optimization and precision medicine. Three tiers available.
Evaluation Consultation
Current clinical status and diagnostic plan.
60 to 90 minutes
In-Depth Diagnostics
Expanded biomarker panel and therapeutic plan.
One to two visits within a week
Longevity Program
Comprehensive optimization with twelve-month follow-up.
Annual program with quarterly reassessment

International patients
Care in Quito, coordinated from New York with Dr. Kristina Zumbana. Medical history review, treatment planning and remote follow-up in six languages.
Information for international patientsTherapeutic apheresis is a medical procedure that separates blood components to selectively remove one of them — usually plasma with its pathological contents — and return the rest to the patient. It is an established medical procedure, distinct from dialysis (which removes waste in patients with kidney failure) and from intravenous therapies (which add substances). It has well-established clinical indications in autoimmune, neurological and other diseases.
No. No serious medical center guarantees results, since the response to any treatment depends on individual patient variables. We share with the patient the available clinical evidence, the expected outcomes based on the medical literature, and the known limitations of each procedure.
Regulatory status varies by procedure and country. Therapeutic apheresis is an internationally established medical procedure. Cell therapy and other regenerative medicine interventions have different regulatory frameworks depending on the country. We discuss the applicable regulatory framework for each procedure with every patient before treatment begins.
It depends on the clinical case. In some cases, our procedures are the primary indication (for example, plasmapheresis in Guillain-Barré syndrome). In oncology, our practice is strictly complementary to the patient's primary cancer treatment and always coordinated with the treating oncology team.
The first consultation lasts 60 to 90 minutes. It includes a complete review of the medical history, physical exam, discussion of clinical goals and definition of the diagnostic plan. For international patients, it can be done virtually before travel.
The duration and magnitude of the clinical response varies depending on the condition, individual patient characteristics and adherence to follow-up recommendations. This is discussed in detail when building the treatment plan.
We coordinate with some international medical insurers. Specific coverage depends on each policy. To verify coverage, we recommend checking before booking the initial consultation.
Through the form on this website, by email at nexusmedclinic@gmail.com or by phone. The clinical coordination team responds within one business day at the latest.